Eli Lilly's obesity drug gets Medicare coverage for sleep apnea
Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, ...
Daily Independent7h
Understanding the dangers of untreated sleep apnea
There are many consequences of untreated OSA, and all of these are more likely with more-severe obstruction. Because people with OSA don't sleep well, they are at a higher risk for motor vehicle ...
Lilly's Zepbound to be covered by Medicare for sleep apnea
Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...
Anti-snoring AI Motion Pillow tracks sleep health and improves sleep quality — here's how
Studies show that snoring is a common sleep issue faced by around 37 million Americans regularly. While there may be a host ...
Medicare can now cover Eli Lilly's Zepbound for sleep apnea, CMS says
It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...
Business Insider14h
CMS confirms to CNBC Medicare plans can now cover Zepbound for sleep apnea
The Centers for Medicare & Medicaid Services confirmed to CNBC that Medicare drug plans can now cover Eli Lilly’s (LLY) obesity drug Zepbound for obstructive sleep apnea, reported Annika Kim ...
FDA approves first ever medication for obstructive sleep apnea — here's what that means
Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.
Future Market Insights1d
Global Continuous Positive Airway Pressure (CPAP) Market Poised for Sustained Growth, Reaching USD 900 Million by 2033 rise at a CAGR of 6%
The global continuous positive airway pressure (CPAP) market is projected to reach a value of USD 900 million by 2033, ...